Viridian Therapeutics, Inc. VRDN Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Viridian Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s return on equity?
- Viridian Therapeutics, Inc. (VRDN) reported return on equity of -58.1% in Q1 2026.
- How has Viridian Therapeutics, Inc.'s return on equity changed year-over-year?
- Viridian Therapeutics, Inc.'s return on equity decreased by 11.9% year-over-year, from -51.9% to -58.1%.
- What is the long-term trend for Viridian Therapeutics, Inc.'s return on equity?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s return on equity has grown at a -21.3% compound annual growth rate (CAGR), from -163.1% to -49.2%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.